WO2001035810A3 - Immunotherapie et diagnostic du cancer utilisant du cytochrome p450 1b1 - Google Patents

Immunotherapie et diagnostic du cancer utilisant du cytochrome p450 1b1 Download PDF

Info

Publication number
WO2001035810A3
WO2001035810A3 PCT/US2000/031513 US0031513W WO0135810A3 WO 2001035810 A3 WO2001035810 A3 WO 2001035810A3 US 0031513 W US0031513 W US 0031513W WO 0135810 A3 WO0135810 A3 WO 0135810A3
Authority
WO
WIPO (PCT)
Prior art keywords
cytochrome
diagnosis
cancer immunotherapy
immunotherapy
provides methods
Prior art date
Application number
PCT/US2000/031513
Other languages
English (en)
Other versions
WO2001035810A2 (fr
Inventor
Joachim L Schultze
Robert H Vonderheide
David Sherr
Lee M Nadler
Britta Maecker
Bergwelt-Baildon Michael Von
Original Assignee
Dana Farber Cancer Inst Inc
Univ Boston
Joachim L Schultze
Robert H Vonderheide
David Sherr
Lee M Nadler
Britta Maecker
Von Bergwelt Baildon Michael
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Univ Boston, Joachim L Schultze, Robert H Vonderheide, David Sherr, Lee M Nadler, Britta Maecker, Von Bergwelt Baildon Michael filed Critical Dana Farber Cancer Inst Inc
Priority to US10/130,413 priority Critical patent/US7385023B1/en
Priority to EP00980436A priority patent/EP1241945A4/fr
Priority to CA002390882A priority patent/CA2390882A1/fr
Publication of WO2001035810A2 publication Critical patent/WO2001035810A2/fr
Publication of WO2001035810A3 publication Critical patent/WO2001035810A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés destinés à réaliser une immunothérapie et un diagnostic du cancer utilisant du cytochrome P450 1B1 et des fragments peptidiques de ce composé.
PCT/US2000/031513 1999-11-15 2000-11-15 Immunotherapie et diagnostic du cancer utilisant du cytochrome p450 1b1 WO2001035810A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/130,413 US7385023B1 (en) 2000-11-15 2000-11-15 Cancer immunotherapy and diagnosis using cytochrome P450 1B1
EP00980436A EP1241945A4 (fr) 1999-11-15 2000-11-15 Immunotherapie et diagnostic du cancer utilisant du cytochrome p450 1b1
CA002390882A CA2390882A1 (fr) 1999-11-15 2000-11-15 Immunotherapie et diagnostic du cancer utilisant du cytochrome p450 1b1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16559099P 1999-11-15 1999-11-15
US60/165,590 1999-11-15

Publications (2)

Publication Number Publication Date
WO2001035810A2 WO2001035810A2 (fr) 2001-05-25
WO2001035810A3 true WO2001035810A3 (fr) 2002-01-10

Family

ID=22599560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031513 WO2001035810A2 (fr) 1999-11-15 2000-11-15 Immunotherapie et diagnostic du cancer utilisant du cytochrome p450 1b1

Country Status (3)

Country Link
EP (1) EP1241945A4 (fr)
CA (1) CA2390882A1 (fr)
WO (1) WO2001035810A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4194365B2 (ja) 2000-10-31 2008-12-10 エムジーアイ ファーマ バイオロジックス インコーポレイテッド Ｃｙｐ１ｂ１核酸および使用の方法
GB0223696D0 (en) * 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
WO2004067549A2 (fr) * 2003-01-31 2004-08-12 Max-Delbrück-Centrum für Molekulare Medizin Peptides diriges contre des autoanticorps resultant de l'intolerance au froid, et leur utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025813A1 (fr) * 1998-10-29 2000-05-11 Dana-Farber Cancer Institute IMMUNOTHERAPIE ET DIAGNOSTIC DU CANCER AU MOYEN D'ANTIGENES UNIVERSELS ASSOCIES A DES TUMEURS TELS QUE hTERT

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519490D0 (en) * 1995-09-25 1995-11-29 Melvin William T Use of a cytochrome P450 enzyme in tumour cells as a marker and target
GB9906380D0 (en) * 1999-03-19 1999-05-12 Melvin William T Monoclonal antibodies specific for cypibi

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025813A1 (fr) * 1998-10-29 2000-05-11 Dana-Farber Cancer Institute IMMUNOTHERAPIE ET DIAGNOSTIC DU CANCER AU MOYEN D'ANTIGENES UNIVERSELS ASSOCIES A DES TUMEURS TELS QUE hTERT

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CANCER EPIDEMIOLOGY, BIOMARKERS PREV., vol. 8, no. 2, 1999, pages 139 - 146 *
CANCER RES., vol. 60, no. 13, 2000, pages 3454 - 3460 *
DATABASE CAPLUS [online] HEIDEL ET AL.: "Cytochrome P4501B1 mediates induction of bone marrow cytotoxicity and preleukemia cells in mice treated with 7,12-dimethylbenz(a)anthracene", XP002941044, accession no. STN Database accession no. 2000:494217 *
DATABASE CAPLUS [online] SPENCER ET AL.: "Quantitative analysis of constitutive and 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin-induced cytochrome P450 1B1 expression in human lymphocytes", XP002941045, accession no. STN Database accession no. 1999:203774 *
DATABASE WPI Derwent World Patents Index; AN 2000-365402, XP002941043, HAHN ET AL.: "Universal tumor-associated antigens such as telomerase catalytic subunit capable of binding major histocompatibility complex molecule useful for diagnosis, prevention and treatment of cancer" *

Also Published As

Publication number Publication date
EP1241945A4 (fr) 2005-08-17
EP1241945A2 (fr) 2002-09-25
CA2390882A1 (fr) 2001-05-25
WO2001035810A2 (fr) 2001-05-25

Similar Documents

Publication Publication Date Title
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2002215345A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002339865A1 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
AU2002316576A1 (en) Diagnostic and screening methods for bladder cancer
AU2002360766A1 (en) Methods for cancer imaging
WO2002081646A3 (fr) Sequences d'epitopes
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
AU2002321872A1 (en) Abrasive particles, and methods of making and using the same
WO2001075178A3 (fr) Methodes d'identification d'aptameres peptidiques pouvant alterer un phenotype cellulaire
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
AU1465801A (en) Methods for cancer prognosis and diagnosis
AU2002305117A1 (en) Improved apparatus, methods and compositions for biotechnical separations
AU4224599A (en) Anti-prostate cancer vaccines, and methods of making, using and evaluating the same
WO1999025843A3 (fr) Kinase humaine de controle, hcds1, compositions et procedes
AU2002342053A1 (en) Pancreatic cancer diagnosis and therapies
AU2002308642A1 (en) Methods for treating cancer
WO2001035810A3 (fr) Immunotherapie et diagnostic du cancer utilisant du cytochrome p450 1b1
AU2002337943A1 (en) Novel compositions and methods for cancer
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AUPQ037799A0 (en) Methods for diagnosing and/or predicting the risk of gastric cancer
AU2002365104A1 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
AU2003294272A1 (en) Methods for diagnosing the presence or stage of cancer
AU5632500A (en) Cancer associated antigens and uses therefor
IL160242A0 (en) Methods for the treatment and prognosis of leukemia and other cancer types

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2390882

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000980436

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000980436

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000980436

Country of ref document: EP